Metabolic signatures and predictive biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study

Background: Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to the need for precise patient management and the absence of effective p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaorong Su, Yiyin Weng, Yiqi Xiao, Lizhu Weng, Yanbin Zeng, Wanlong Lin, Wei Zhuang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-01-01
coleção:	Cancer Treatment and Research Communications
Assuntos:	Liposomal doxorubicin Hypersensitivity Breast cancer Biomarker Metabolomics
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2468294226000158
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!